Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
Infect Chemother. 2017 Jun;49(2):135-139. English. Brief Communication. https://doi.org/10.3947/ic.2017.49.2.135
Suh HJ , Kim I , Cho JY , Park SI , Yoon SH , Lee JO , Koh Y , Song KH , Choe PG , Yu KS , Kim ES , Kim HB , Bang SM , Kim NJ , Song SH , Park WB , Oh MD .
Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea. wbpark1@snu.ac.kr
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea.
Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, Korea.
Department of Laboratory Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea.
Abstract

The posaconazole tablet formulation was developed to have improved bioavailability compared to the oral suspension. Here, we compared posaconazole plasma concentration (PPC) with the posaconazole oral suspension versus the tablet in Korean patients undergoing remission induction chemotherapy for hematologic malignancies. PPC was measured at 3, 8, and 15 days of treatment with the oral suspension (174 patients) or the tablet (40 patients). At all time-points, mean PPC was significantly higher with the tablet compared to the oral suspension. Our findings suggest that posaconazole tablets generate an optimal PPC earlier and in more patients than the oral suspension among Korean patients.

Copyright © 2019. Korean Association of Medical Journal Editors.